Skip to main content
Top
Published in: Neurosurgical Review 4/2018

01-10-2018 | Original Article

The role of surgery in intracranial PCNSL

Authors: Guro Jahr, Michele Da Broi, Harald Holte Jr, Klaus Beiske, Torstein R. Meling

Published in: Neurosurgical Review | Issue 4/2018

Login to get access

Abstract

This aimed to evaluate the effect of surgery for overall survival (OS) and progression-free survival (PFS) in intracranial primary CNS lymphoma (PCNSL) of all patients diagnosed at a single center. A prospective database at Oslo University Hospital of PCNSL was reviewed over a 12-year period (2003–2014). Seventy-nine patients with intracranial PCNSL were identified. Deep brain involvement was shown in 63 patients. Thirty-two patients underwent craniotomy with resection, while all other patients had a biopsy. Fifty-seven patients were given chemotherapy: 18 were treated with the MSKCC (Memorial Sloan-Kettering Cancer Center) with rituximab, 21 with the MSKCC without rituximab, and 14 within a Nordic prospective phase II protocol. Forty-four patients achieved complete response (CR) and had OS of 46.3 months. Patients who underwent resection had a median OS of 28.6 versus 11.7 months for those who had a biopsy performed. Resection showed an insignificant prolongation of OS. Multivariate analysis confirmed statistical significance of deep brain involvement only (p < 0.005). Neither chemotherapy regimen, Karnofsky Performance Status (KPS), type of surgery, nor patient age was significant factors for OS or PFS. Resective surgery played no role in significantly improving either OS or PFS and therefore it is not recommended as treatment for PCNSL.
Literature
5.
go back to reference Bierman PJ (2014) Surgery for primary central nervous system lymphoma: is it time for reevaluation? Oncology (Williston Park) 28(7):632–637 Bierman PJ (2014) Surgery for primary central nervous system lymphoma: is it time for reevaluation? Oncology (Williston Park) 28(7):632–637
6.
go back to reference Cloney MB, Sonabend AM, Yun J, Yang J, Iwamoto F, Singh S, Bhagat G, Canoll P, Zanazzi G, Bruce JN, Sisti M, Sheth S, Connolly ES, McKhann G (2017) The safety of resection for primary central nervous system lymphoma: a single institution retrospective analysis. J Neuro-Oncol 132(1):189–197. https://doi.org/10.1007/s11060-016-2358-8 CrossRef Cloney MB, Sonabend AM, Yun J, Yang J, Iwamoto F, Singh S, Bhagat G, Canoll P, Zanazzi G, Bruce JN, Sisti M, Sheth S, Connolly ES, McKhann G (2017) The safety of resection for primary central nervous system lymphoma: a single institution retrospective analysis. J Neuro-Oncol 132(1):189–197. https://​doi.​org/​10.​1007/​s11060-016-2358-8 CrossRef
8.
go back to reference Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F, IELSG (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374(9700):1512–1520. https://doi.org/10.1016/s0140-6736(09)61416-1 CrossRefPubMed Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F, IELSG (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374(9700):1512–1520. https://​doi.​org/​10.​1016/​s0140-6736(09)61416-1 CrossRefPubMed
9.
go back to reference Ghesquières H, Ferlay C, Sebban C, Perol D, Bosly A, Casasnovas O, Reman O, Coiffier B, Tilly H, Morel P, Van den Neste E, Colin P, Haioun C, Biron P, Blay JY (2010) Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Ann Oncol 21(4):842–850. https://doi.org/10.1093/annonc/mdp529 CrossRefPubMed Ghesquières H, Ferlay C, Sebban C, Perol D, Bosly A, Casasnovas O, Reman O, Coiffier B, Tilly H, Morel P, Van den Neste E, Colin P, Haioun C, Biron P, Blay JY (2010) Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Ann Oncol 21(4):842–850. https://​doi.​org/​10.​1093/​annonc/​mdp529 CrossRefPubMed
10.
go back to reference Korfel A, Thiel E, Martus P, Möhle R, Griesinger F, Rauch M, Röth A, Hertenstein B, Fischer T, Hundsberger T, Mergenthaler HG, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Weller M (2015) Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology 84(12):1242–1248. https://doi.org/10.1212/wnl.0000000000001395 CrossRefPubMed Korfel A, Thiel E, Martus P, Möhle R, Griesinger F, Rauch M, Röth A, Hertenstein B, Fischer T, Hundsberger T, Mergenthaler HG, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Weller M (2015) Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology 84(12):1242–1248. https://​doi.​org/​10.​1212/​wnl.​0000000000001395​ CrossRefPubMed
13.
go back to reference Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A (2013) Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol 31(31):3971–3979. https://doi.org/10.1200/jco.2013.50.4910 CrossRefPubMedPubMedCentral Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A (2013) Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol 31(31):3971–3979. https://​doi.​org/​10.​1200/​jco.​2013.​50.​4910 CrossRefPubMedPubMedCentral
15.
go back to reference Pulczynski EJ, Kuittinrn O, Erlanson M, Hagberg H, Nordstrøm M, Østenstad B, Fluge Ø, Leppä S, Fiirgaard B, Bersvendsen H, Fagerli U-M, Alexander, Eriksson M (2015) Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic lymphoma group. Hematologica 100(4):534–540. https://doi.org/10.3324/haematol.2014.108472 CrossRef Pulczynski EJ, Kuittinrn O, Erlanson M, Hagberg H, Nordstrøm M, Østenstad B, Fluge Ø, Leppä S, Fiirgaard B, Bersvendsen H, Fagerli U-M, Alexander, Eriksson M (2015) Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic lymphoma group. Hematologica 100(4):534–540. https://​doi.​org/​10.​3324/​haematol.​2014.​108472 CrossRef
Metadata
Title
The role of surgery in intracranial PCNSL
Authors
Guro Jahr
Michele Da Broi
Harald Holte Jr
Klaus Beiske
Torstein R. Meling
Publication date
01-10-2018
Publisher
Springer Berlin Heidelberg
Published in
Neurosurgical Review / Issue 4/2018
Print ISSN: 0344-5607
Electronic ISSN: 1437-2320
DOI
https://doi.org/10.1007/s10143-018-0946-0

Other articles of this Issue 4/2018

Neurosurgical Review 4/2018 Go to the issue